Literature DB >> 31418414

A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt.

Yinglong Li1, Xiaofeng He2, Huajin Pang2.   

Abstract

BACKGROUND/AIMS: Early hepatic encephalopathy (HE) is one of the most common complications developed after undergoing transjugular intrahepatic portosystemic shunt (TIPS). Hence, its early prevention and treatment are important. This study aimed at establishing a model to predict early post-TIPS HE.
MATERIALS AND METHODS: Clinical data of 262 patients who underwent TIPS procedure was analyzed retrospectively. Patients were divided into early post-TIPS HE and non-early post-TIPS HE groups, based on the presence of HE within 3 months after TIPS. About 70% of the patients were randomly selected as the model group to establish a prediction model, and the remaining 30% were used as the validation group to test the model. The independent risk factors for early HE post-TIPS were identified and selected using single factor analysis and multi-factor logistic regression analysis. Subsequently the prediction model was established and validated.
RESULTS: Age, Child-Pugh classification, and fibrinogen were found to be the independent risk factors for early post-TIPS HE., The logistic regression model was established based on these factors and their regression coefficients: p=1/{1+exp[4.829-1.975*age-1.110*(Child-Pugh classification)+1.724*loge (fibrinogen in g/L)]}. Finally, the model was validated among a set of 79 patients from the validation group.
CONCLUSION: The logistic regression model based on age, Child-Pugh classification, and fibrinogen for early post-TIPS HE can effectively predict the risk of early HE after TIPS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31418414      PMCID: PMC6699572          DOI: 10.5152/tjg.2019.18485

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  12 in total

Review 1.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Oliviero Riggio; Silvia Nardelli; Federica Moscucci; Chiara Pasquale; Lorenzo Ridola; Manuela Merli
Journal:  Clin Liver Dis       Date:  2012-01-04       Impact factor: 6.126

2.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Yasutaka Mamiya; Hidenori Kanazawa; Yuu Kimura; Yoshiyuki Narahara; Yuuichirou Yamate; Katsuhisa Nakatsuka; Choitsu Sakamoto
Journal:  Hepatol Res       Date:  2004-11       Impact factor: 4.288

3.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

4.  Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.

Authors:  Leigh C Casadaban; Ahmad Parvinian; Jeet Minocha; Janesh Lakhoo; Christopher W Grant; Charles E Ray; M Grace Knuttinen; James T Bui; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

5.  Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy.

Authors:  Z Hassoun; M Deschênes; M Lafortune; M P Dufresne; P Perreault; L Lepanto; D Gianfelice; B Bui; G Pomier-Layrargues
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

Review 6.  Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review.

Authors:  Ming Bai; Xingshun Qi; Zhiping Yang; Zhanxin Yin; Yongzhan Nie; Shanshan Yuan; Kaichun Wu; Guohong Han; Daiming Fan
Journal:  J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 4.029

7.  Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Oliviero Riggio; Lorenzo Ridola; Chiara Pasquale; Silvia Nardelli; Ilaria Pentassuglio; Federica Moscucci; Manuela Merli
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-15       Impact factor: 11.382

8.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

9.  Transjugular intrahepatic portosystemic shunt induced short- and long-term cerebral blood flow variations in cirrhotic patients: an arterial spin labeling MRI study.

Authors:  Gang Zheng; Long Jiang Zhang; Yue Cao; Zhiying Pan; Rong Feng Qi; Ling Ni; Donghong Shi; Xinxin Fan; Guang Ming Lu
Journal:  Metab Brain Dis       Date:  2013-04-07       Impact factor: 3.584

10.  Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease.

Authors:  Charmaine A Stewart; Michael Malinchoc; W Ray Kim; Patrick S Kamath
Journal:  Liver Transpl       Date:  2007-10       Impact factor: 5.799

View more
  2 in total

1.  Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Zhong Wang; Yi-Fan Wu; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Yu Zhang; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2021-02-07       Impact factor: 5.742

2.  Development and Validation of Prognostic Models to Estimate the Risk of Overt Hepatic Encephalopathy After TIPS Creation: A Multicenter Study.

Authors:  Chongtu Yang; Xiaoli Zhu; Jiacheng Liu; Qin Shi; Hang Du; Yang Chen; Songjiang Huang; Chen Zhou; Yingliang Wang; Tongqiang Li; Yaowei Bai; Bin Xiong
Journal:  Clin Transl Gastroenterol       Date:  2022-01-27       Impact factor: 4.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.